Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00333216 · ClinicalTrials.gov registry record · Phase 3
Anecortave Acetate Risk-Reduction Trial (AART)
A Phase 3 study, sponsored by Alcon Research.
- Terminated
- Registry status
- Phase 3
- Development phase
- 24
- Enrollment target
NCT00333216: Clinical Trial Phase 3 study, sponsored by Alcon Research.
NCT00333216 is a Phase 3 study that was terminated before completion, run by Alcon Research. The registered enrollment target is 24 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00333216, a Phase 3 study, was terminated before completion, sponsored by Alcon Research.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study was to demonstrate that Anecortave Acetate for Depot Suspension (15 mg or 30 mg) is safe and effective in arresting the progression of non-exudative (dry) age-related macular degeneration in patients who are at risk for progressing to exudative (wet) age-related macular degeneration.
Interventions
- DRUG Anecortave Acetate Sterile Suspension, 30 mg/mL
- OTHER Anecortave Acetate Vehicle
- DRUG Anecortave Acetate Sterile Suspension, 60 mg/ML
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2005-05 |
| Est. Completion | 2008-12 |
| Phase | Phase 3 |
Why NCT00333216 stopped before completion
NCT00333216 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 3 interventions - of which Anecortave Acetate Sterile Suspension, 30 mg/mL is the first listed.
NCT00333216 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00333216 about?
NCT00333216 is a clinical study titled "Anecortave Acetate Risk-Reduction Trial (AART)". The purpose of this study was to demonstrate that Anecortave Acetate for Depot Suspension (15 mg or 30 mg) is safe and effective in arresting the progression of non-exudative (dry) age-related macular degeneration in patients who are at risk for progressing to exudative (wet) age-related macular deg...
What is the current status of trial NCT00333216?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 24 participants. The study started on 2005-05. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00333216?
The interventions under investigation include: Anecortave Acetate Sterile Suspension, 30 mg/mL (DRUG), Anecortave Acetate Vehicle (OTHER), Anecortave Acetate Sterile Suspension, 60 mg/ML (DRUG).
Who is sponsoring clinical trial NCT00333216?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00333216's enrollment target sits among peer trials
24 1943rd of 2000 higher than 49 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia